These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 14719194

  • 21. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F.
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [Abstract] [Full Text] [Related]

  • 22. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C.
    Arthritis Res Ther; 2004 Feb; 6(3):R264-72. PubMed ID: 15142273
    [Abstract] [Full Text] [Related]

  • 23. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment.
    Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, Chronopoulou E, Trachana M.
    Cytokine; 2008 Jun; 42(3):293-7. PubMed ID: 18445529
    [Abstract] [Full Text] [Related]

  • 24. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH, Bingham SJ, Bryer D, Emery P.
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [Abstract] [Full Text] [Related]

  • 25. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.
    Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL.
    J Rheumatol; 2007 May; 34(5):952-7. PubMed ID: 17444589
    [Abstract] [Full Text] [Related]

  • 26. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS.
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [Abstract] [Full Text] [Related]

  • 27. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 28. Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation.
    Novak S, Anić B, Anić F, Cerovac M, Cikeš N.
    Acta Dermatovenerol Croat; 2011 Feb; 19(3):156-60. PubMed ID: 21933639
    [Abstract] [Full Text] [Related]

  • 29. Infliximab-induced autoantibodies: a multicenter study.
    Vaz JL, Fernandes V, Nogueira F, Arnóbio A, Levy RA.
    Clin Rheumatol; 2016 Feb; 35(2):325-32. PubMed ID: 26676808
    [Abstract] [Full Text] [Related]

  • 30. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y.
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [Abstract] [Full Text] [Related]

  • 31. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
    Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, Van Hartingsveldt B, Mascelli MA, Graham MA, Durez P, Bouman-Thio E.
    J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
    [Abstract] [Full Text] [Related]

  • 32. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, Keenan G.
    Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
    [Abstract] [Full Text] [Related]

  • 33. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.
    Bingham SJ, Buch MH, Kerr MA, Emery P, Valadäo Barcelos AT.
    Arthritis Rheum; 2004 Dec; 50(12):4072-3. PubMed ID: 15593202
    [No Abstract] [Full Text] [Related]

  • 34. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P.
    Arthritis Res Ther; 2006 Dec; 8(4):R131. PubMed ID: 16869978
    [Abstract] [Full Text] [Related]

  • 35. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 36. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN.
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [Abstract] [Full Text] [Related]

  • 37. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
    Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T.
    Ann Rheum Dis; 2008 Feb; 67(2):189-94. PubMed ID: 17644554
    [Abstract] [Full Text] [Related]

  • 38. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
    Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, Cohen SB, Gangnon RE, Schiff MH.
    J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
    [Abstract] [Full Text] [Related]

  • 39. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group.
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [Abstract] [Full Text] [Related]

  • 40. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.